awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q33408546-6DD48D56-CB2B-4A60-83A3-104CEF108699
Q33408546-6DD48D56-CB2B-4A60-83A3-104CEF108699
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33408546-6DD48D56-CB2B-4A60-83A3-104CEF108699
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.
P2860
Q33408546-6DD48D56-CB2B-4A60-83A3-104CEF108699
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33408546-6DD48D56-CB2B-4A60-83A3-104CEF108699
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b7351fff9109f1eb1b376f75264c72c77c6838d2
P2860
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.